Immunome (NASDAQ:IMNM) Insider Sells $334,224.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the transaction, the insider owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 2.0%

Shares of IMNM opened at $23.93 on Friday. The company has a market capitalization of $2.72 billion, a P/E ratio of -9.46 and a beta of 2.13. The firm has a 50 day moving average of $25.32 and a 200 day moving average of $22.77. Immunome, Inc. has a twelve month low of $9.06 and a twelve month high of $30.06.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, sell-side analysts expect that Immunome, Inc. will post -2.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IMNM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Wedbush boosted their price target on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Truist Financial upped their price target on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Wall Street Zen lowered shares of Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.64.

Hedge Funds Weigh In On Immunome

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allworth Financial LP acquired a new position in shares of Immunome in the second quarter valued at about $25,000. Integrated Wealth Concepts LLC purchased a new stake in Immunome in the second quarter valued at approximately $27,000. KBC Group NV acquired a new position in Immunome in the 1st quarter worth approximately $60,000. Assetmark Inc. lifted its stake in Immunome by 46.6% during the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after acquiring an additional 1,442 shares during the period. Finally, State of Wyoming acquired a new stake in Immunome during the 2nd quarter valued at approximately $109,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.